Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON31359
NL-OMON31359
Completed
Not Applicable

Prevention of psychosis with a cognitive behavioural intervention in help-seeking young people with an at risk mental state for developing psychosis - EDIE-NL Early Detection Intervention Evaluation - Netherlands

Parnassia (Den Haag)0 sites240 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Parnassia (Den Haag)
Enrollment
240
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Parnassia (Den Haag)

Eligibility Criteria

Inclusion Criteria

  • •At Risk Mental State (see page 7 and 8 of protocol)
  • •Age 18 to 35 years

Exclusion Criteria

  • •current or previous receipt of antipsychotic medication
  • •moderate to severe learning disability; organic impairment
  • •non\-Dutch speaking

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
The prevention of psychosis in at risk mental state
ISRCTN21353122The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)240
Recruiting
Not Applicable
Prevention of psychosis with a cognitive behavioural intervention in help-seeking young people with an at risk mental state for developing psychosis.1. At risk mental state<br />2. psychosis<br />3. prevention<br />4. ultrahoog risico<br />5. psychose<br />6. preventie.
NL-OMON23126Vrije Universiteit, Vakgroep Klinische Psychologie.240
Completed
Not Applicable
Primary prevention of psychosis through interventions in the prodromal phase
ISRCTN20328848Stavanger University Hospital (Norway)240
Completed
Phase 4
Second generation intervention research in the pre-psychotic phase of illness in schizophrenia and related psychosesSchizophrenia and other psychotic disordersMental Health - SchizophreniaMental Health - Other mental health disorders
ACTRN12605000247673Janssen-Cilag Pharmaceuticals119
Active, not recruiting
Phase 1
Hydrocortisone as co-treatment to prevent neuropsychiatric adverse effects of dexamethasone.europsychiatric adverse effects which can be caused by dexamethasone. For example delirium, anxiety, depression, mania and psychosis. But also cognitive impairment and sleep disturbance.Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2017-003705-17-NLMC180